Current Cardiology Reviews最新文献_第3页

Novel Strategies to Improve the Cardioprotective Effects of Cardioplegia. 改善心脏麻痹对心脏保护作用的新策略

IF 2.4

Current Cardiology Reviews Pub Date : 2024-01-24 DOI: 10.2174/011573403X263956231129064455

Estefanie Osorio-Llanes, Jairo Castellar-López, Wendy Rosales-Rada, Yulieth Montoya, John Bustamante, Ricardo Zalaquett, Roberto Bravo-Sagua, Jaime A Riquelme, Gina Sánchez, Mario Chiong, Sergio Lavandero, Evelyn Mendoza-Torres

{"title":"Novel Strategies to Improve the Cardioprotective Effects of Cardioplegia.","authors":"Estefanie Osorio-Llanes, Jairo Castellar-López, Wendy Rosales-Rada, Yulieth Montoya, John Bustamante, Ricardo Zalaquett, Roberto Bravo-Sagua, Jaime A Riquelme, Gina Sánchez, Mario Chiong, Sergio Lavandero, Evelyn Mendoza-Torres","doi":"10.2174/011573403X263956231129064455","DOIUrl":"10.2174/011573403X263956231129064455","url":null,"abstract":"The use of cardioprotective strategies as adjuvants of cardioplegic solutions has become an ideal alternative for the improvement of post-surgery heart recovery. The choice of the optimal cardioplegia, as well as its distribution mechanism, remains controversial in the field of cardiovascular surgery. There is still a need to search for new and better cardioprotective methods during cardioplegic procedures. New techniques for the management of cardiovascular complications during cardioplegia have evolved with new alternatives and additives, and each new strategy provides a tool to neutralize the damage after ischemia/reperfusion events. Researchers and clinicians have committed themselves to studying the effect of new strategies and adjuvant components with the potential to improve the cardioprotective effect of cardioplegic solutions in preventing myocardial ischemia/reperfusion-induced injury during cardiac surgery. The aim of this review is to explore the different types of cardioplegia, their protection mechanisms, and which strategies have been proposed to enhance the function of these solutions in hearts exposed to cardiovascular pathologies that require surgical alternatives for their corrective progression.","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11071679/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139564011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardiac Axis in Early Gestation and Congenital Heart Disease. 妊娠早期的心轴与先天性心脏病

IF 2.4

Current Cardiology Reviews Pub Date : 2024-01-24 DOI: 10.2174/011573403X264660231210162041

D Carrasco, L Guedes-Martins

引用次数: 0

Physiological Evidence and Therapeutic Outcomes of Vitamin D on Cardiovascular Diseases. 维生素 D 对心血管疾病的生理证据和治疗效果。

IF 2.4

Current Cardiology Reviews Pub Date : 2024-01-18 DOI: 10.2174/011573403X263417231107110618

Abolfazl Zendehdel, Amir Shakarami, Ehsan Sekhavati Moghadam

引用次数: 0

Understanding the Role of Galectin-1 in Heart Failure: A Comprehensive Narrative Review. 了解 Galectin-1 在心力衰竭中的作用：全面叙述性综述。

IF 2.4

Current Cardiology Reviews Pub Date : 2024-01-08 DOI: 10.2174/011573403X274886231227111902

Mohammad Javad Sotoudeheian, Seyed-Mohamad-Sadegh Mirahmadi, Mohammad Pirhayati, Reza Azarbad, Soroush Nematollahi, Mehdi Taghizadeh, Hamidreza Pazoki-Toroudi

{"title":"Understanding the Role of Galectin-1 in Heart Failure: A Comprehensive Narrative Review.","authors":"Mohammad Javad Sotoudeheian, Seyed-Mohamad-Sadegh Mirahmadi, Mohammad Pirhayati, Reza Azarbad, Soroush Nematollahi, Mehdi Taghizadeh, Hamidreza Pazoki-Toroudi","doi":"10.2174/011573403X274886231227111902","DOIUrl":"10.2174/011573403X274886231227111902","url":null,"abstract":"Heart failure (HF) is the fastest-growing cardiovascular condition worldwide. The immune system may play a role in the development of HF since this condition is associated with elevated pro-inflammatory cytokine levels. HF is a life-threatening disease, and there is an increasing demand for diagnostic biomarkers, prognostic factors, and therapeutic agents that can help treat it. Galectin-1 (Gal-1) is the prototype galectin of the lectin family. Multiple signal transduction pathways are regulated by Ras proteins, which act as a molecular switch in cells. Gal-1 regulates T and B cell activation, differentiation, and survival. Gal-1 has been linked to inflammation. Activated T cells produce Gal-1 through an autocrine apoptotic mechanism involving MEK1/ERK and p38 MAPK. In the cardiovascular system, atherosclerosis is facilitated by Gal-1. Heart disease, myocardial infarction, hypertension, and stroke can be caused by atherosclerotic plaque. HF and heart hypertrophy are caused by decreased cardiac L-type Ca2+ channel activity. Deregulation of Gal-1 and CaV1.2 in pathological cardiac hypertrophy suggests a possible target for anti-hypertrophic therapy. Rat hypertrophic cardiomyocytes express Gal-1 and CaV1.2 channels simultaneously. It has been reported that diastolic dysfunction (DD) is associated with elevated Gal-1 levels. The high Gal-1 level in subjects led to the lowest cumulative survival as a composite endpoint. Incidences of HF, DD, and serum Gal-1 levels correlated significantly. The ejection fraction was negatively correlated with Gal-1 and CRP concentrations. Based on two different approaches in mice and humans, Gal-1 was identified as a potential mediator of HF.","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11071677/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139402176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association Between Nutrients and Cardiovascular Diseases. 营养素与心血管疾病之间的关系。

IF 2.4

Current Cardiology Reviews Pub Date : 2024-01-05 DOI: 10.2174/011573403X263414231101095310

Amir Shakarami

引用次数: 0

Percutaneous Patent Foramen Ovale Closure: Stroke and Beyond. 经皮闭孔器：中风及其他。

IF 2.4

Current Cardiology Reviews Pub Date : 2024-01-01 DOI: 10.2174/011573403X276984240304044109

Sandeep Randhawa, Jawahar L Mehta, Gaurav Dhar

{"title":"Percutaneous Patent Foramen Ovale Closure: Stroke and Beyond.","authors":"Sandeep Randhawa, Jawahar L Mehta, Gaurav Dhar","doi":"10.2174/011573403X276984240304044109","DOIUrl":"10.2174/011573403X276984240304044109","url":null,"abstract":"Over 750,000 individuals suffer from stroke annually in the United States, with 87% of these strokes being ischemic in nature. Roughly 40% of ischemic strokes occur in individuals 60 years of age or under. A quarter of all ischemic strokes have no identifiable cause despite extensive workup and are deemed cryptogenic in nature. Patent Foramen Ovales (PFO) has been postulated in stroke causation by either paradoxical embolization or platelet activation in the tunnel of the defect. The incidence of PFO is reported to be 15-25% in the general population but rises to 40% in patients with cryptogenic stroke. While the initial trials evaluating PFO closures were non-revealing, subsequent long-term follow-ups, as well as recent trials evaluating PFO closures in cryptogenic stroke patients 60 years of age or under, demonstrated the superiority of percutaneous closure compared to medical therapy alone, leading to FDA approval of PFO closure devices. In this review, we review the diagnosis of PFO, postulated stroke mechanisms, literature supporting PFO closure, patient selection for percutaneous closure, procedural considerations, and associated procedural complications.","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11284695/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140130959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Atrial Thrombus or Atrial Myxoma? Preliminary Analysis of Echocardiographic Findings of a Case Series. 心房血栓还是心房肌瘤？一个病例系列的超声心动图结果初步分析。

IF 2.4

Current Cardiology Reviews Pub Date : 2024-01-01 DOI: 10.2174/011573403X281926240417110330

Guobing Hu, Fang Song

{"title":"Atrial Thrombus or Atrial Myxoma? Preliminary Analysis of Echocardiographic Findings of a Case Series.","authors":"Guobing Hu, Fang Song","doi":"10.2174/011573403X281926240417110330","DOIUrl":"10.2174/011573403X281926240417110330","url":null,"abstract":"Background: Echocardiography has been proven to be a useful tool for detecting atrial-occupying lesions, ranging from primary or secondary tumors to thrombi. Although the precise diagnosis is important as clinical treatment modalities differ, sometimes differentiating a thrombus from a myxoma is very difficult.Case report: From January 2019 to December 2022, we retrospectively analyzed the echocardiographic findings of 8 patients who were found to have an interatrial mass. Of the 8 patients, 4 had a right atrial mass, and 4 had a left atrial mass. Based on ultrasonic examination, the initial diagnosis was a thrombus and the second diagnosis was a myxoma for all 8 patients. All masses were finally confirmed to be thrombi. Although an echocardiogram can provide significant information on the nature of atrial masses in many patients, qualitative diagnosis of a small percentage of atrial masses remains difficult.Conclusion: An atrial thrombus is occasionally difficult to differentiate from an atrial myxoma in patients without atrial fibrillation, especially when it is not attached to the left atrial appendage. Upon review of the echocardiographic findings of the 8 patients described in our study, it is essential to highlight the fact that a thrombus can mimic a myxoma and thereby create a diagnostic conundrum.","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11337610/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140854054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardiac Amyloidosis in Venezuela: A Pending Issue. 委内瑞拉的心脏淀粉样变性：一个悬而未决的问题。

IF 2.4

Current Cardiology Reviews Pub Date : 2024-01-01 DOI: 10.2174/011573403X305835240715092532

Juan Salazar, Mayela Bracho, Carlos Esis, Roberto Añez-Ramos

引用次数: 0

Aldosterone Effect on Cardiac Structure and Function. 醛固酮对心脏结构和功能的影响

IF 2.4

Current Cardiology Reviews Pub Date : 2024-01-01 DOI: 10.2174/011573403X281390240219063817

Ekhlas Mahmoud Al-Hashedi, Fuad A Abdu

{"title":"Aldosterone Effect on Cardiac Structure and Function.","authors":"Ekhlas Mahmoud Al-Hashedi, Fuad A Abdu","doi":"10.2174/011573403X281390240219063817","DOIUrl":"10.2174/011573403X281390240219063817","url":null,"abstract":"Background: Cardiac remodelling could be a key mechanism in aldosteronemediated cardiovascular morbidity and mortality. Experimental and clinical evidence has demonstrated that aldosterone causes cardiac structural remodelling and dysfunction by its profibrotic and pro-hypertrophic effects, which result mainly from the direct effects on myocardial collagen deposition, inflammation, and oxidative stress. Clinical studies have investigated the aldosterone effects on the heart in different clinical conditions, including general population, essential hypertension, primary aldosteronism, heart failure, and atrial fibrillation. Robust findings indicate that aldosterone or the activation of the cardiac mineralocorticoid receptor can cause damage to myocardial tissue by mechanisms independent of the blood pressure, leading to tissue hypertrophy, fibrosis, and dysfunction.Conclusion: Aldosterone-mediated cardiovascular morbidity and mortality mainly result from cardiac structural and functional alterations. In different clinical settings, aldosterone can induce cardiac structural remodelling and dysfunction via several pathological mechanisms, including cardiac fibrosis, inflammation, and oxidative stress. Aldosterone antagonists could effectively decrease or reverse the detrimental aldosterone-mediated changes in the heart.","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11327832/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139995828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Volatilome: A Novel Tool for Risk Scoring in Ischemic Heart Disease. Volatilome：缺血性心脏病风险评分的新工具

IF 2.4

Current Cardiology Reviews Pub Date : 2024-01-01 DOI: 10.2174/011573403X304090240705063536

Basheer Abdullah Marzoog

引用次数: 0